← All Quanterix CORP filings

Quanterix CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
QTRX
Quanterix CORP
10-K: Quanterix: Akoya Integration, Alzheimer's Test Advance
Quanterix reports increased revenue driven by strategic acquisitions and progress in Alzheimer's diagnostics, despite a significant rise in net loss and macroeconomic headwinds.
NASDAQ
QTRX
Quanterix CORP
10-K/A: Quanterix Files Amendment No. 1 to Form 10-K/A to Include Part III Information
Quanterix Corporation files an amendment to its annual report to include information required by Part III of Form 10-K, which was initially omitted.
NASDAQ
QTRX
Quanterix CORP
10-K: Quanterix Reports FY2024 Results, Announces Akoya Biosciences Acquisition
Quanterix's FY2024 results show revenue growth and strategic acquisitions aimed at expanding its presence in diagnostics and biomarker analysis.
NASDAQ
QTRX
Quanterix CORP
10-K/A: Quanterix Restates Financials Due to Inventory Valuation Error, Cites Material Weakness in Controls
Quanterix Corporation has filed an amended annual report to restate its financial statements for the past three years due to an error in inventory valuation and other unrelated errors, revealing a material weakness in internal controls.
NASDAQ
QTRX
Quanterix CORP
10-K: Quanterix Amends Non-Employee Director Compensation Policy, Effective January 1, 2024
Quanterix Corporation has updated its Non-Employee Director Compensation Policy, outlining changes to cash retainers and equity awards for non-employee board members, effective January 1, 2024.